11 analysts' median target is $394[FMP target], stock is $285, +38.0% upside potential. After Q1 +-12.8% EPS beat[FMP earnings], the stock moved -6.5%.
B = MoonshotScore 50[9-pillar formula] + Council 5/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].
Q4 consensus: revenue $6.6B[FMP est], EPS $3.47[FMP est]. 0 consecutive quarters of beat[FMP earnings].
Q1 EPS +-12.8% beat[FMP] but the stock -6.5% D+1[FMP D+1]. Preston Wells promised $166.0M CapEx + a sequential decline in Q4 during the Q1 earnings call[Preston Wells capex transcript].
Watchlist
Procedural Volumes And Capex
procedural_volumes_and_capex
Stryker is seeing solid procedural volumes supported by favorable demographics and the continued adoption of robotic-assisted surgery, as well as a steady hospital CapEx environment.
"Procedural volumes were solid, supported by favorable demographics and the continued adoption of robotic-assisted surgery. The hospital CapEx environment also remains steady, and our capital order book remains elevated as we enter the remainder of the year."
- Jason Beach, Vice President of Finance and Investor Relations - Q1 FY26 Earnings Call - April 30, 2026
Fy26 Guidance Maintained
fy26_guidance_maintained
Stryker is maintaining its full year guidance for both revenue and earnings per share despite disruptions from the cyber incident.
"Despite the disruption we experienced this quarter, we are maintaining our full year guidance."
- Preston Wells, CFO - Q1 FY26 Earnings Call - April 30, 2026
Mako Installations Q1
mako_installations_q1
Stryker delivered its best ever Q1 for Mako installations both in the U.S. and internationally, with high and increasing utilization rates across the globe.
"Additionally, we delivered our best ever Q1 for Mako installations both in the U.S. and internationally, with high and increasing utilization rates across the globe."
- Jason Beach, Vice President of Finance and Investor Relations - Q1 FY26 Earnings Call - April 30, 2026
Cyber Incident Impact
cyber_incident_impact
The cyber incident meaningfully impacted Stryker's first quarter results, but the company expects normalization over the course of the year and is maintaining its full year guidance.
"While our growth this quarter was meaningfully impacted by the cyber incident, we remain encouraged by the solid fundamentals in the markets we serve and remain well positioned within them. As a result, we are maintaining our full year guidance and look forward to another year of healthy performance in 2026."
- Kevin Lobo, Chair and Executive Officer - Q1 FY26 Earnings Call - April 30, 2026
Amplitude Vascular Systems Acquisition
amplitude_vascular_systems_acquisition
Stryker announced the agreement to acquire Amplitude Vascular Systems to help expand treatment options for peripheral vascular customers and is also a step toward expanding our presence in the broader cardiovascular space.
"On the M&A front, we recently announced the agreement to acquire Amplitude Vascular Systems that we expect to close in the second quarter. The acquisition of AVS will help expand treatment options for our peripheral vascular customers and is also a step toward expanding our presence in the broader cardiovascular space."
- Kevin Lobo, Chair and Executive Officer - Q1 FY26 Earnings Call - April 30, 2026
Ortho Tech Business
ortho_tech_business
Stryker established its new Ortho Tech business by combining the Mako and Enabling Technologies with the Orthopaedic Instruments portfolio to simplify the customer experience, accelerate innovation and increase our speed to market.
"Also, at the beginning of Q1, we established our new Ortho Tech business by combining the Mako and Enabling Technologies with the Orthopaedic Instruments portfolio from our Instruments business to simplify the customer experience, accelerate innovation and increase our speed to market."
- Kevin Lobo, Chair and Executive Officer - Q1 FY26 Earnings Call - April 30, 2026
Stock Expert AI - Methodology
9-pillar methodology. Cash Runway and News Sentiment strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 5 bullish (Ray Dalio, Jim Simons, Klarman, Buffett, Munger), 1 bearish (Ken Griffin), 0 neutral (none).
How is it calculated? ->Quality business, discounted price.
How is it calculated? ->Past Performance
Q1 (April 30, 2026): EPS $2.60 vs $2.98 est[FMP], +-12.8% beat. D+1 movement: -6.5%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.
Q1: EPS $2.60 vs $2.98 beat[FMP], stock -6.5% D+1[FMP].
No RPO/backlog concentration disclosed in Q1 earnings call.
Q1 CapEx $166.0M[FMP cashflow]. Q1 op margin 15.5%[FMP op margin] - this level in Q4 is sensitive to CapEx revision risk.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $3.47[FMP], CapEx threshold "below $166.0M"[Preston Wells]. Two anchors, three scenarios.
Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore 9-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This SYK (SYK) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.